NAD+ 100mg
Lower-dose NAD+ researched for cellular energy and longevity.
NAD+ 100mg
Background
This is a lower-dose (100 mg) presentation of nicotinamide adenine dinucleotide (NAD+), an endogenous coenzyme central to cellular redox metabolism and a substrate for sirtuin and PARP enzymes. Research interest centers on age-related decline in NAD+ and the metabolic, mitochondrial, and DNA-repair consequences of restoring cellular NAD+ levels.
Mechanistic evidence derives largely from cellular and animal models; clinical investigation of NAD+ precursors is ongoing.
Selected literature
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529-547.
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Nicotinamide adenine dinucleotide is a naturally occurring endogenous coenzyme and is not a trademarked product. Supplied as reference material only.
